

Hermine Agis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2933706/publications.pdf>

Version: 2024-02-01

55
papers

675
citations

623734

14
h-index

610901

24
g-index

56
all docs

56
docs citations

56
times ranked

1316
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis. <i>Journal of Intensive Care Medicine</i> , 2019, 34, 723-731.	2.8	86
2	Lightâ€chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. <i>European Journal of Heart Failure</i> , 2020, 22, 1852-1862.	7.1	82
3	CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. <i>Transplantation</i> , 2021, 105, 451-457.	1.0	57
4	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by ¹⁸ F-Fluoride and ¹⁸ F-FDG. <i>Journal of Nuclear Medicine</i> , 2017, 58, 968-974.	5.0	40
5	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 742-761.	1.9	31
6	Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia*. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 936-953.	3.8	30
7	Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. <i>Journal of Clinical Apheresis</i> , 2017, 32, 224-234.	1.3	28
8	Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. <i>BMC Cancer</i> , 2018, 18, 1008.	2.6	27
9	Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 512-524.	1.2	26
10	Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1831-1838.	1.3	23
11	Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. <i>Clinical Research in Cardiology</i> , 2021, 110, 532-543.	3.3	21
12	Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 502-511.	7.1	17
13	Hemophagocytic lymphohistiocytosis in COVID-19. <i>Medicine (United States)</i> , 2021, 100, e25170.	1.0	17
14	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281.	0.7	16
15	Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of-Concept Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1334.	2.4	13
16	Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. <i>Leukemia Research</i> , 2005, 29, 1227-1232.	0.8	12
17	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. <i>Blood</i> , 2020, 136, 50-51.	1.4	12
18	Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2022, 15, .	2.6	12

#	ARTICLE	IF	CITATIONS
19	Haematopoietic stem cell transplantation for treatment of primary ¹⁸F-FDG-PET/CT and ¹⁸F-NaF-PET/CT lymphoma: single-centre experience and literature review. European Journal of Haematology, 2015, 95, 75-82.	2.2	10
20	Amyloid in the heart: an under-recognized threat at the interface of cardiology, haematology, and pathology. European Heart Journal Cardiovascular Imaging, 2016, 17, 978-980.	1.2	10
21	Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. Journal of Clinical Medicine, 2020, 9, 2234.	2.4	10
22	Impaired efferocytosis by monocytes in multiple myeloma. Oncology Letters, 2018, 16, 409-416.	1.8	9
23	N-terminal B-type natriuretic peptide (NT-proBNP) is associated with disease severity in multiple myeloma. European Journal of Clinical Investigation, 2018, 48, e12905.	3.4	8
24	Detection of Trisomy 8 in Donor-Derived Ph ⁺ Cells in a Patient with Ph ⁺ Chronic Myeloid Leukemia Successfully Treated with Imatinib (STI571) in Relapse after Allogeneic Transplantation. Leukemia and Lymphoma, 2004, 45, 1453-1458.	1.3	7
25	Corneal Toxicity Associated With Belantamab Mafodotin Is Not Restricted to the Epithelium: Neuropathy Studied With Confocal Microscopy. American Journal of Ophthalmology, 2022, 242, 116-124.	3.3	7
26	Hemodynamic Profiles and Their Prognostic Relevance in Cardiac Amyloidosis. Journal of Clinical Medicine, 2020, 9, 1093.	2.4	6
27	The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers, 2021, 13, 4701.	3.7	6
28	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood, 2021, 138, 153-153.	1.4	6
29	Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy. Wiener Klinische Wochenschrift, 2022, 134, 478-482.	1.9	6
30	Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging. Journal of Personalized Medicine, 2021, 11, 1268.	2.5	5
31	News in AL Amyloidosis ASH 2016. Memo - Magazine of European Medical Oncology, 2017, 10, 66-71.	0.5	4
32	Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response. Annals of Hematology, 2020, 99, 2599-2609.	1.8	4
33	Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2) Tj ETQq1 1 0.784314 rgBT /Overlaid	1.4	4
34	Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02). Blood, 2019, 134, 696-696.	1.4	4
34	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	4.5	4
35	Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. Cancers, 2021, 13, 5886.	3.7	4
36	Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using ¹⁸F-FDG-PET/CT and ¹⁸F-NaF-PET/CT. Anticancer Research, 2019, 39, 1943-1952.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Renal Expression of Light Chain Binding Proteins. <i>Frontiers in Medicine</i> , 2020, 7, 609582.	2.6	2
38	Does Renal Failure Affect Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma?. <i>Blood</i> , 2016, 128, 4642-4642.	1.4	2
39	Structural analysis of urinary light chains and proteomic analysis of hyaline tubular casts in light chain associated kidney disorders. <i>PeerJ</i> , 2019, 7, e7819.	2.0	2
40	Riociguat for the treatment of transthyretin cardiac amyloidosis: data from a named patient use program in Austria. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	1.7	1
41	Immunoglobulin light chain amyloidosis. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 103-110.	0.5	1
42	Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.. <i>Blood</i> , 2005, 106, 3516-3516.	1.4	1
43	Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.. <i>Blood</i> , 2004, 104, 4755-4755.	1.4	1
44	Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study. <i>Blood</i> , 2018, 132, 2018-2018.	1.4	1
45	Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series. <i>Blood</i> , 2019, 134, 3123-3123.	1.4	1
46	SP295LONGITUDINAL EVALUATION OF RENAL FUNCTION IN MULTIPLE MYELOMA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i443-i443.	0.7	0
47	Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 80-88.	0.5	0
48	Paraprotein-associated diseases: a complex relationship between monoclonal gammopathy of unknown significance and severe organ damage. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 9-10.	0.5	0
49	Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.. <i>Blood</i> , 2004, 104, 4754-4754.	1.4	0
50	Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.. <i>Blood</i> , 2007, 110, 4556-4556.	1.4	0
51	Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients.. <i>Blood</i> , 2009, 114, 4263-4263.	1.4	0
52	BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.. <i>Blood</i> , 2010, 116, 3382-3382.	1.4	0
53	Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM O2 Study). <i>Blood</i> , 2021, 138, 1669-1669.	1.4	0
54	Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM O2 Study). <i>Blood</i> , 2020, 136, 29-30.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial). Blood, 2020, 136, 27-29.	1.4	0